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ABSTRACT 
Glioblastoma (GBM) remains a highly lethal brain tumor that continues have overall low survival 
rate, with only 5% of patients to five or more years. This thesis proposes a drug- and polymersome-
loaded thermosensitive hydrogel as a therapeutic platform to target and eliminate post-surgical 
GBM tumor cells. The experiments presented lay some foundational work in establishing the 
feasibility of and optimizing such a platform. Polyethene glycol (PEG)-Polyester pH-responsive 
polymersomes were synthesized, optimized and conjugated with peptide ligands to increase cellular 
uptake in vitro. A Python workflow was designed, using RNAseq data from the Cancer Genome 
Atlas (TCGA) and the Genotype-Tissue Expression project (GTEx) with online proteomic and 
binding databases, to find GBM cellular surface targets and the ligands that bind them. A 
biomimetic hydrogel, enhanced by chemotaxis signaling molecules, was synthesized as an 
alternative tumor eliminating modality. The continuation of this work, merging modern 
nanomedicine synthesis techniques and disease-specific data analysis promises to have positive 
implications for GBM patient prognosis.  
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1 – INTRODUCTION 
After decades of research, glioblastoma (GBM) remains an aggressive, incurable and lethal brain 
tumor with a median survival time of approximately 15 months1. Within two years, many patients 
develop recurrent tumors in the periphery of the resection cavity, leading, in nearly every case, to 
death2. GBM continues to have a low overall survival rate, with only 5% of patients living to five 
or more years3,4. The current “gold standard” treatment for GBM is to surgically remove all 
accessible tumor mass followed by a combination of radiotherapy and oral temozolomide (TMZ) 
chemotherapy3,5–8. Treatment with TMZ only increases the median survival of patients by an 
average of four months, as GBM cells rapidly become resistant to the cytotoxic drug9 (figure 1.1). 
 
Figure 1.1 – Kaplan-Meier survival plots for glioblastoma multiforme cases according to year of 
diagnosis and age. (A) 20–44 years. (B) 45–64 years. (C) 65–79 years. (D) 80+ years. Note that 
2005-2007 data is in the era of TMZ and reflects the slight increase in median survival time. 
Adapted from10. 
2 
 
Barriers to GBM Treatment 
Treatment Gap 
There is a time gap, generally 2-3 weeks, between surgical resection of the GBM tumor and when 
oral TMZ and radiotherapy begins11–13. Despite recent advances in tumor surgery for GBM14,15, 
even extensive tumor resections may leave behind invasive tumor cells, as they can evade detection 
by radiological imaging2. A small population of tumor cells, free to migrate and proliferate for 
weeks in a wound healing environment, could be responsible for seeding a recurrent tumor. 
Blood Brain Barrier 
The blood brain barrier, (BBB) selectively transports molecules and cells to and from the central 
nervous system (CNS), and acts as a barrier to pathogens and harmful chemicals16,17. This barrier, 
formed by endothelial cells that form tight junctions, prevents 98% of small molecule drugs from 
crossing from plasma of blood into the interstitial or cerebrospinal fluid of the brain18,19. Generally, 
only small lipophilic drugs can passively diffuse across the BBB20. This drastically lowers the 
number of intravenous and oral therapeutic drug candidates available for treating GBM. 
General Toxicity 
Chemotherapeutics, when taken orally or intravenously, often have off-target toxicity in sensitive 
systems, like the kidneys, lungs and heart21. This puts a limit on the drug dosages that doctors are 
able to use to treat GBM tumors. TMZ has a particularly toxic effect on bone marrow and liver 
during treatment of GBM22. In some cases, particularly among the elderly, TMZ actually shortens 
the survival time of the patient due to adverse effects23. These drugs are not only acutely toxic to 
sensitive systems, but can lead to long-term secondary malignancies and sterility24. 
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Temozolomide Resistance 
Even, though TMZ is capable of crossing the BBB, at least half of all patients treated with TMZ 
do not respond to the drug. Tumors that do respond quickly become resistant to the drug, in as few 
as one dose25. The cytotoxic effect of alkylating drugs like TMZ is stopped by O6-methylguanine 
DNA-methyltransferase (MGMT), a suicide repair protein25,26. Attempts to target MGMT with a 
small molecule drug or inhibitor, to hinder TMZ resistance,  have not been successful9. 
GBM Tumor Cell Heterogeneity 
GBM tumor cells are phenotypically heterogeneous. Within the same tumor, there can be  several, 
phenotypically diverse sub-populations of tumor cells27–29. Furthermore, there is evidence that 
GBM tumor cells are plastic, and can shift phenotypes in response to environmental stimuli, 
including surgery and chemotherapy30,31. The heterogeneous and dynamic nature of GBM tumor 
cells makes them difficult to treat with a single drug and is the driving force behind combination 
drug therapy research for GBM. 
Table 1.1 – Summary of Barriers to GBM Treatment 
Treatment Gap 
• Radiotherapy and TMZ treatment 2-3 weeks after tumor 
resection. 
• Unresected GBM tumor cells can migrate and proliferate, 
leading to recurrent tumors. 
General Toxicity 
• Oral or intravenous chemotherapeutics lead to toxicity 
complications across vital systems in the body 
• Off-target toxicity limits doses of cytotoxic drugs 
Blood Brain Barrier (BBB) • Prevents more than 98% of small molecule drugs from reaching the brain, limiting  
TMZ Resistance • GBM tumor cells rapidly become resistant to cytotoxic agents, even after a single dose 
Tumor Cell Heterogeneity 
• GBM cells are phenotypically diverse, even in the same 
tumor. 
• Tumors are dynamic and plastic, able to change phenotype 
in response to environment 
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Local Delivery by Nanoparticle-Loaded Hydrogels 
Local drug delivery, in this case, delivering a drug directly into the GBM tumor resection site, has 
the potential to overcome several treatment barriers. The drug can be implanted during resection 
surgery, eliminating the treatment gap. This would also circumvent complications associated with 
the BBB, as the drug would not have to cross from the blood plasma to the CNS. Moreover, as the 
drug would not be circulating through the body in the bloodstream, concerns about toxicity in 
sensitive systems would be eliminated. The question remains, as to how to deliver the drug to the 
tumor cells with a sufficient dosage for long enough to eliminate the tumor mass.  
Two drug delivery devices that have been researched for decades are drug-carrying hydrogels and 
polymeric nanoparticles. A full review of these systems is beyond the scope of this text. However, 
this section will focus on what makes these drug delivery tools attractive for local treatment of 
GBM tumors. 
Hydrogels 
Hydrogels are networks of hydrophilic polymers that remain insoluble due to crosslinking between 
the polymer chains. These networks are capable of holding aqueous solutions of drugs and other 
therapeutic molecules32.  These hydrogels can be synthesized from polymers that can undergo 
conformational change when affected by an internal (pH, temperature, redox) or external (enzyme, 
magnetic, light) stimulus33,34. Conformational changes can facilitate either the gelation or 
degradation of the hydrogel, and when implanted, can be used as a mechanism for releasing a drug 
solution into surrounding tissues35,36. A recently popular class of stimuli-responsive hydrogels for 
the local treatment of GBM is thermosensitive hydrogels37–40. These solutions remain liquid at room 
temperature, but gelate at physiological temperatures, holding a drug solution in place. This is 
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attractive for GBM treatment because a drug-loaded hydrogel can be injected directly into the 
tumor resection site during surgery, where the drug can treat the remaining tumor cells. 
Polymeric Nanoparticles 
Polymeric nanoparticles are nanoscale, highly-dispersed, solid structures, made from synthetic or 
organic polymers41. They have a variety of different functional geometries and are capable of 
encapsulating hydrophilic and/or hydrophobic drugs41–45. Like hydrogels, when synthesized with 
stimuli-responsive polymers, nanoparticles can undergo conformational changes or degradation, in 
response to a stimulus,  as a mechanism for releasing drugs46–50. Recently, several researchers have 
begun to employ drug-carrying nanoparticles to target and treat GBM tumors51–53. 
Nanoparticle-Loaded Hydrogels 
In  2010, Arai et al. combined nanoparticles a with thermosensitive hydrogel, demonstrating that 
the coupling of their properties resulted in prolonged release and therapeutic effects of doxorubicin 
in vivo54. Since then, researchers have been combining nanoparticle and hydrogel systems to create 
nanoparticle-loaded hydrogels and nanohydrogels (hydrogels synthesized by crosslinking 
nanoparticles) 37,40,55,56 (Figure 1.2).  
 
Figure 1.2 – Nanoparticle loaded hydrogels. (a) nanoparticles entrapped in polymer network (b) 
nanoparticles with physical interactions in polymer matrix (c) nanoparticles as the crosslinkers for 
polymer network (d) nanogel made from crosslinked nanoparticles. Adapted from 40. 
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Recently, for treatment in GBM, Bastinach et al. demonstrated that a Lauroyl-gemcitabine 
nanoparticle-based hydrogel (GemC12-LNC) lowered the rate of GBM recurrence when surgically 
implanted in U87 mouse models. GemC12-LNC was also tolerated in these mouse models for up 
to six months, suggesting a very low systemic toxicity38. 
Nanoparticle-loaded hydrogels are an attractive platform for the treatment of GBM, as the 
combination of stimuli-responsive modalities can facilitate combination therapy and more control 
over drug release dynamics.  
A Systems Biology Approach 
TMZ resistance and GBM tumor cell heterogeneity are not barriers to GBM treatment that can be 
overcome by formulating a new nanoparticle or hydrogel. These complications are a consequence 
of the still ambiguous disease biology. To solve these problems, a greater understanding of GBMs 
underlying biological mechanisms is required. Fortunately, systems biologists have been able to 
employ genetic, transcriptomic, proteomic and metabolomic data to classify and quantify GBM 
tumor cells in a number of useful ways.  
For TMZ resistance, a number of different researchers are analyzing data and building models to 
quantify and combat the mechanisms underlying MGMT repair and understand the prognostic 
value of MGMT promoter methylation9,26,57,58. To better understand GBM heterogeneity, 
researchers are combining new surgical sampling techniques with genomic analysis to track the 
evolution dynamics of tumor cell populations31. Other biologists are using single-cell 
transcriptomic data and gene-expression based analysis in an effort classify distinct GBM subtypes 
for future researchers27,59. In addition, Databases like the Cancer Genome Atlas (TCGA), Cancer 
Cell Line Encyclopedia (CCLE) and International Cancer Genome Consortium (ICGC) provide 
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enormous, curated, cancer-specific datasets that help inform the fields of drug discovery and 
pharmacology60.  
The continuing growth of publicly available biological data and improved analysis methodologies 
is crucial to understanding GBM. This analysis can uncover methods to effectively target and 
eliminate GBM tumor cells, and is fundamental in informing material, drug and delivery modalities 
for future drug delivery systems. 
Thesis and Overview 
Using stimuli-responsive polymers to create a drug- and nanoparticle-loaded hydrogel, we can 
overcome the barriers to improving GBM treatment and improve patient survival. The hydrogel is 
to be injected intracranially, filling the cavity of tumor resection, where it releases both a cytotoxic 
drug for a short period (<48 hrs), and targeting, drug-loaded polymersomes for a longer period (~40 
days). This mode of localized drug delivery erases the complications of crossing the BBB and 
systemic toxicity, while simultaneously eliminating the treatment time gap and post-surgical 
proliferation of GBM tumor cells. Polymersomes with functionalized surfaces, encapsulating 
targeted cancer drugs, facilitate drug delivery and elimination of the diverse array of GBM cell 
phenotypes within a patient’s residual tumor. 
This text will lay the foundation for the described drug delivery platform for treating GBM. 
Chapters 1 focuses on synthesizing and optimizing nanoparticle properties for local treatment of 
GBM. Chapter 2 extends the functionality of these particles through the conjugation of surface 
ligands, in an effort to increase cellular particle uptake. Chapter 3 introduces a workflow to 
elucidate GBM cellular surface targets and the ligands that bind them from transcriptomic datasets 
and proteomic databases. Chapter 4 explores a novel tumor elimination modality using biomimetic 
hydrogels loaded with chemotaxis signaling molecules.  
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2 – POLYMERSOMES FOR LOCAL DELIVERY IN GBM 
Introduction 
Amphiphilic block copolymers self-assemble, under aqueous conditions, into a variety of 
nanoparticle geometries. However, for polyethylene glycol (PEG) based copolymers, when the 
mass of the hydrophilic block is between ~35% ± 10% they assemble into a hollow vesicle known 
as a polymersome61. The hydrophobic blocks of the copolymer forms a hydrophobic bilayer 
surrounding an aqueous core. This allows the nanoparticle to carry hydrophobic drugs in the 
membrane interior and hydrophilic drugs in the core62 (Figure 2.1). Being able to control the 
chemical properties and molecular weight of the polymers, polymersomes typically have thicker, 
more chemically stable membranes than earlier drug nanoparticles with similar geometries, like 
liposomes63.  
 
Figure 2.1 – Illustration of a cross section of a polymersome. The hydrophobic membrane (red) 
encapsulates hydrophobic molecules while the aqueous core encapsulates water-soluble 
compounds. Adapted from 62. 
 
There are a variety of polymers that can undergo conformational change when affected by a 
stimulus. When block copolymers are synthesized using these stimuli-responsive polymers, they 
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can assemble into polymersomes that degrade or undergo conformational change in response to 
internal (pH, temperature, redox) and external (enzyme, magnetic, light) stimuli by degradation or 
conformational change. These mechanisms can be exploited to control drug release from either 
aqueous or hydrophobic compartments of the nanoparticles46–49.  There has been research 
performed using these stimuli-responsive polymersomes for the treatment of GBM53. Using 
internal stimuli, Jiang et al. engineered redox-responsive polymersomes to effectively deliver 
saporin, a protein toxin therapeutic, in GBM mouse models64. In contrast, Luo et al. used high-
intensity focused ultrasound, an external stimuli, to trigger release and effective delivery of 
doxorubicin and perfluorooctyl bromide in a U87 mouse model65.  
PH-triggered drug release is attractive mechanism for cancer treatment, due to the acidity of both 
the tumor microenvironment and tumor cell endosomes46. Polymersomes assembled from 
copolymers with blocks degradable by acid hydrolysis, like polyesters, can be designed to degrade 
at different rates in acidic conditions66. It has also been shown that nanoparticles with PEG on their 
surface avoid uptake by phagocytic cells as part of the reticuloendothelial system in vivo67. This is 
attractive for long-term local therapy of GBM, as microglia are phagocytes that digest particles 
within the CNS68. 
Polymersomes synthesized from PEG-polyester block copolymers can benefit from both controlled 
pH-responsive controllable release and evasion of microglia in the brain. This chapter explores 
material and synthesis design choices to for engineering polymersomes optimized for local delivery 
to GBM tumor cells.  
Methods 
Solvent Injection Method for Synthesis of Polymersomes – 1 mg diblock copolymer methoxy 
polyethylene glycol polylactide (1kDa-5kDa, Polysciences Inc #24381-1) polyethylene glycol 
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polycaprolactone (2kDA-5kDA) (Aldrich #900648) (PEGPCL) was dissolved in 100 μL miscible 
organic solvent dimethyl sulfoxide (VWR BDH Chemicals  #BDH1115-1LD) (DMSO), N-methyl-
2-pyrrolidone (VWR Life Science #89500-566) (NMP) or N,N-dimethylformamide (BDH 
Chemicals #BDH83634.100) (DMF). In a 4 dram threaded vial, the solution was injected via 0.5 
mL syringe (BD #305602) by nano-syringe pump (KD Scientific) into 10 mL continuously stirring 
2wt%/v mannitol (BDH VWR Analytical #BDH9248) or inulin (Alfa Aesar #A18425) in water at 
a constant rate of 5 μL/min. 
Emulsion Evaporation Method for Synthesis of Polymersomes – 1 mg diblock copolymer 
methoxy polyethylene glycol polylactide (1kDa-5kDa, Polysciences Inc #24381-1) (PEGPLA) or 
methoxy polyethylene glycol polycaprolactone (2kDA-5kDA) (Aldrich #900648) (PEGPCL) was 
dissolved in 1 mL immiscible solvent dichloromethane (VWR BDH Chemicals #BDH23373.100E) 
(DCM). The solvent solution was added to 9 mL 0.5 wt%/v Pluronic F-68 (Gibco #24040-032) in 
water in an 11 dram threaded vial. The mixture was emulsified using a homogenizer (Thermo 
Fisher), three cycles of 5 sec on/5 sec off at 50% power. The vial containing the emulsion was 
connected to a Rotavapor R-100 (Buchi) via 24/40 vial adapter (Chemglass #CG-1318-40) and 
rotated under vacuum until bubbling stopped and solution was clear. 
Lyophilization and Characterization of Polymersomes – Polymersome solution was frozen 
slowly, first to -20°C for 6 hours, then to -80°C overnight, in a 50 mL conical tube. The solution 
was then then lyophilized at 0.04 mbar and -105°C by FreeZone lyophilizer (LABCONCO). 
Polymersome diameters and zeta potential were measured by dynamic light scattering (DLS) via 
Zetasizer Nano ZS (Malvern). 
Loading of Polymersomes – Lyophilized polymersomes were rehydrated in 1 mL aqueous 
solution (0.16 mg/mL in water) of Alexa Fluor 488 carboxylic acid tris(triethylammonium) salt 
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(Invitrogen #A33077) (AF488). Unencapsulated AF488 was separated from loaded polymersomes 
by centrifugal filter device (Amicon 0.5 mL 100K #UFC5100BK), spinning three times at 14000g 
for 10 minutes in a 5424R centrifuge (Eppendorf). Encapsulation efficiency (EE) was determined 
with the following equation: 
𝐸𝐸𝐸𝐸(%) = 100% − (𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝑚𝑚𝑇𝑇𝑚𝑚𝑚𝑚 (𝑚𝑚𝑚𝑚) 𝑇𝑇𝑜𝑜 𝐴𝐴𝐴𝐴488 𝑖𝑖𝑖𝑖 𝑜𝑜𝑖𝑖𝑇𝑇𝑇𝑇𝑓𝑓𝑇𝑇𝑇𝑇𝑓𝑓𝑚𝑚0.16 𝑚𝑚𝑚𝑚  × 100%) 
Mass of AF488 in filtrates was calculated using a linear calibration curve (relative fluorescence 
units (RFU) vs. AF488 concentration). Fluorescence measurements were made with Synergy H1 
microplate reader (BioTek). 
Experimental Results and Discussion 
The goal of these experiments is to optimize polymersome properties for local delivery in GBM. 
The ideal polymersome will have a diameter between 10-200 nm, to prevent rapid clearance by the 
renal system and opsonization by phagocytes in the reticuloendothelial system33,  be monodisperse, 
and be capable of carrying both hydrophobic and/or hydrophilic molecules for delivery. The 
polymersomes should also have a significant negative zeta potential, a proxy for nanoparticle 
surface charge, and indicator of colloidal stability in solution69.  It is also important that the 
polymersomes are capable of releasing these molecules in a pH-responsive manner for delivery in 
either the acidic GBM tumor microenvironment or acidic intracellular vesicles. Another important 
metric to be considered is whether the polymersomes can be lyophilized for long term storage and 
rehydrated for future use. These experiments focus on choosing copolymers, synthesis methods 
and lyoprotectants to synthesize polymersomes ideal for GBM delivery. 
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PEGPLA polymersomes in 2wt%/v mannitol in water – The  solvent injection method employed 
for synthesizing polymersomes is adapted from Kelly et al70. Table 2.1 shows the size, 
polydispersity and zeta potential of the resulting particles. 
Table 2.1 – PEGPLA Polymersomes in 2%wt/v Mannitol – DLS Measurements 
Diameter (nm) PDI Zeta Potential (mV) 
149.00 ± 13.63 0.088 ± 0.022 -30.56 ± 0.91 
 
These polymersomes are in the desired size range, are monodisperse (polydispersity index (PDI) < 
0.3)71 and have a large negative zeta potential. Also, the polylactic acid block comprising the 
hydrophobic membrane is pH-responsive by acid hydrolysis. These characteristics make these 
polymersomes a good candidate for GBM local delivery, assuming they can be loaded with 
therapeutic molecules and lyophilized for long term storage. 
Lyophilization and loading PEGPLA polymersomes – PEGPLA polymersomes were synthesized 
via solvent injection using 2% mannitol and rehydrated by 0.16 mg/mL AF488 dye solution. AF488 
is a hydrophilic molecule and is encapsulated in the aqueous core of the polymersomes. Dye 
encapsulation efficiency of the polymersomes is shown to be as high as 38.6%, indicating that these 
particles are promising carrier for soluble therapeutic molecules. However, DLS measurements 
indicate that the rehydrated polymersomes are not monodisperse, likely destabilizing and forming 
aggregates (Figure 2.2 (top)). Particles were synthesized in mannitol solutions up to 10%, with 
similar results. 
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Figure 2.2 – Size distribution (Diameter) of rehydrated PEGPLA particles (top) in 2%wt/v 
mannitol in water(bottom) in 2%wt/v inulin in water. 
 
PEGPLA polymersomes were re-synthesized via solvent injection, using 2wt%/v inulin in water as 
the lyoprotectant. It has been shown that inulin, a fructose polymer, is effective at lyoprotection of 
PEG-based polymersomes72,73. The particles are of similar size and dispersity as the mannitol-
protected particles. When these polymersomes are lyophilized and rehydrated using a 0.16 mg/mL 
AF488 dye solution, they maintain their membrane stability and monodisperse nature (Figure 2.2 
(bottom)), albeit with a slight increase in diameter. However, these polymersomes show a lower 
capacity for soluble molecule encapsulation, having an AF488 encapsulation efficiency of 25.4% 
± 2.2%. This is likely due to the larger size of inulin, making it less likely to leave the membrane 
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during rehydration.. Table 2.2 shows the results of DLS measurements on these PEGPLA 
polymersomes. 
Table 2.2 – PEGPLA Polymersomes Before and After Lyophilization – DLS Measurements 
 Before lyophilization Rehydrated after Lyophilization 
Lyoprotectant Diameter (nm) PDI Diameter (nm) PDI 
2% mannitol 167.41 ± 25.29 0.108 ± 0.055 100.48 ± 42.01 0.611 ± 0.350 
2% inulin 122.14 ± 7.74 0.119 ± 0.023 158.22 ± 6.13 0.175 ± 0.033 
 
Another consideration when choosing a lyoprotectant is the characteristics of the solid product. 
Polymersomes lyophilized in mannitol form a powdery substance, easy to store and transfer 
between containers. Polymersomes lyophilized in inulin form a slow-flowing, translucent 
amorphous, solid, which at room temperature can be difficult to handle and transfer. 
While PEGPLA polymersomes are great candidates for pH-responsive delivery of drugs 
intravenously, they may be less stable when subjected to extended time frames in the slightly acidic 
pH conditions of the GBM tumor microenvironment. In this environment, the polymersome 
membrane may prematurely destabilize and release a drug before it is able to reach the GBM tumor 
cell.  Thus, copolymer blocks made with polycaprolactone (PCL) are attractive as the polymer is 
more hydrophobic than PLA. There is a longer carbon chain in each monomer, leading to stronger 
hydrophobic interactions in an aqueous environment. There are also less ester groups, sites for acid 
hydrolysis, per block (Figure 2.3). These characteristics should lead to stronger membrane 
interactions, and longer stability in the acidic tumor microenvironment, while maintaining a pH-
responsive drug release mechanism.  
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Figure 2.3 – Structure of PEG-based block copolymers, (left) PEGPLA. (right) PEGPCL. 
Highlighted in red is the long carbon chain that leads to stronger hydrophobic interactions 
between polymers in solution. 
 
PEGPCL polymersome synthesis – PEGPCL polymersomes were synthesized via solvent injection 
using two different organic solvents, NMP and DMF. This was necessary as PEGPCL is not soluble 
in DMSO, like PEGPLA is Figure 2.4 shows the results of DLS measurement of the PEGPCL 
polymersomes. 
Although PEGPCL particles have smaller diameters when synthesized at the same concentration 
as the PEGPLA polymersomes, it is shown that size can be modulated by controlling the 
concentration of the copolymer in the organic phase during synthesis. 
Figure 2.4 – DLS measurements for PEGPCL polymersomes – solvent injection. 
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While particles synthesized via solvent injection effectively encapsulate soluble compounds in their 
aqueous core, there are GBM therapeutics that have very low solubility in water. There is another 
mode of synthesis, single emulsion evaporation (EE) that simultaneously encapsulate hydrophobic 
molecules with high efficiency74. 
Emulsion evaporation synthesis of PEGPCL polymersomes – PEGPCL polymersomes were 
prepared via EE method, adapted from Khalil et al75, with varying concentrations (0.7, 1, 1.3 mg 
PEGPCL/1 mL DCM). Figure 2.5 shows the DLS measurements for the PEGPCL polymersomes.  
 
Figure 2.5 – DLS measurements for PEGPCL polymersomes – emulsion evaporation method. 
 
At 1 and 0.7 mg PEGPCL/1 mL DCM and lower concentrations, the polymersomes were desirable 
size and monodisperse. At 1.3 mg PEGPCL/1 mL DCM, however, polymersome solutions became 
polydisperse. More curious is that there is a negative correlation between polymer concentration 
and average diameter. This is in contrast to the positive correlation between polymer concentration 
and diameter for solvent injection method discussed earlier. This suggests that polymer 
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concentration may not be the driving force in the polymersome self-assembly process when using 
the EE method. Although literature suggests that size modulation can be achieved through process 
design (homogenization, surfactant content, solvents etc.)74,76,77. 
Conclusions and Future Outlook 
This chapter illustrates the types of material design choices a polymeric nanomedicine researcher 
must make when designing drug delivery systems. Table 2.3 summarizes the material, lyoprotectant 
and synthesis choices explored in this work. 
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Table 2.3 – Advantages and Disadvantages of Varying Copolymer, Lyoprotectant and Synthesis 
Method 
Polymersome Synthesis Method 
 Pros Cons 
Solvent 
Injection 
• Very monodisperse polymersome 
solutions 
• Diameters easily modulated by 
polymer concentration 
• Could be scaled reasonably 
• Inefficient loading of hydrophilic 
molecules when synthesizing and 
loading simultainiously 
Emulsion 
Evaporation 
• Synthesizing and loading of 
polymersomes with hydrophobic 
molecules simultaneous 
• High entrapment of hydrophobic 
molecules 
• Much higher PDI than solvent 
injection method 
 
Lyoprotectant 
 Pros Cons 
Mannitol • Cheap and simple molecule 
• Through rehydration, high 
encapsulation efficiency of water-
soluble molecules 
• Lyophilized polymersomes are 
not monodisperse upon 
rehydration 
• Lyophilized solutions will need 
to be filtered to remove 
aggregates 
Inulin • Lyophilized polymersomes are 
monodisperse upon rehydration 
• No need to filter rehydrated 
polymersome solutions 
• Expensive, large polymer 
molecules 
• Lower encapsulation of water-
soluble molecules through 
rehydration 
Amphiphilic Block Copolymer 
 Pros Cons 
PEGPLA • pH-responsive acid hydrolysis 
excellent mechanism for drug 
release 
• Soluble in less toxic organic 
solvents. 
• Polymersomes may prematurely 
destabilize in acidic tumor 
microenvironment. 
PEGPCL • pH-responsive acid hydrolysis 
excellent mechanism for drug 
release 
• Polymersomes will remain stable 
for longer in acidic tumor 
microenvironment 
• Only soluble in more toxic 
solvents like NMP and DMF 
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Looking forward, for a local delivery system for the treatment of GBM, PEGPCL polymersomes 
are the best nanoparticle on which to build a platform. It has been shown that they can be prepared 
by different methods for the loading of both hydrophilic and hydrophobic therapeutic molecules. 
These polymersomes can also be loaded and lyophilized, with inulin as a lyoprotectant, for long-
term storage. For local delivery in GBM, PEGPCL polymersome solutions can be used to solubilize 
thermosensitive polymers to create polymersome-loaded, temperature-responsive hydrogels. These 
hydrogels can be injected into GBM tumor resection sites for extended local treatment of remaining 
tumor cells. Furthermore, these polymersomes can be functionalized with different ligands to 
enhance biological function, including cell surface targeting and cellular uptake, which will be 
explored in the next chapter. 
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3 – POLYMERSOME LIGAND ATTACHMENT FOR BIOLOGICAL FUNCTION 
Introduction 
Recent research have shown that using ligands to target membrane surface targets can lead to 
increased biological function, like initiating receptor-mediated endocytosis and crossing the blood 
brain barrier (BBB)78. For example, it was demonstrated that functionalizing nanoparticles with 
ApoE, a lipoprotein, will increase the transport of those particles across the blood brain barrier via 
interaction with low-density lipoprotein receptors79, which are overexpressed on BBB interfacial 
cells17,18. The focus of this thesis, local delivery to GBM, is to bypass the BBB entirely, but we can 
use the same concept of active targeting to increase effective drug delivery to GBM cells. In 
particular, polymersomes are effective vessels for getting drugs through the membranes of cells 
when their surfaces are functionalized with ligands, proteins, antibodies and peptides78 (Figure 3.1). 
These functional molecules promote cell adhesion and receptor mediated endocytosis, increasing 
the rate at which drugs are internalized by a cancer tumor cell44,51,78,80. 
 
Figure 3.1 – Illustrative examples of how polymersomes functionalized with targeting ligands 
bind to cellular surface proteins. Adapted from  78. 
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Using active targeting ligands is an attractive modality for the local treatment of GBM. There are 
cellular surface proteins, overexpressed in GBM, capable of being targeted (this be explored more 
thoroughly in the next chapter). The binding affinities of the ligand to those proteins will facilitate 
the preferential delivery of chemotherapeutics to GBM tumor cells. 
This chapter will focus on demonstrating that, by functionalizing the surface of polymersomes 
discussed in Chapter 2, cellular uptake of these polymersomes can be significantly increased in 
vitro. This will provide a platform for synthesizing polymersomes functionalized with active 
targeting ligands, and how to quantify their drug delivery efficiency in vitro.  
Methods 
Embedding Method for Synthesizing Maleimide-Functionalized Polymersomes – 1.5 mg 
diblock copolymer methoxy polyethylene glycol polycaprolactone (2kDA-5kDA) (Aldrich 
#900648) (PEGPCL) and varying masses (5,10,40 mg) of homobifunctional polyethylene 
glycol(3500kDa)-(maleimide)2 (JENKEM Technology USA #A4010-1) (MPEGM) were dissolved 
in 100 μL N,N-dimethylformamide (BDH Chemicals #BDH83634.100) (DMF). In a 2 dram 
threaded vial, the solvent solution was injected via 0.5 mL syringe (BD #305602) by nano-syringe 
pump (KD Scientific) into 1.4 mL continuously stirring Alexa Fluor 488 carboxylic acid 
tris(triethylammonium) salt (Invitrogen #A33077) (AF488) (0.114 mg/mL) in water at a constant 
rate of 5 μL/min. Unencapsulated AF488 and non-embedded MPEGM were separated from loaded 
polymersomes by centrifugal filter device (Amicon 0.5 mL 100K #UFC5100BK), spinning three 
times at 14000g for 10 minutes in a 5424R centrifuge (Eppendorf). 
Synthesizing Maleimide-Functionalized Polymersomes with M-PEGPLGA/PCL – 1 mg 
Poly(ε-caprolactone)-PEG-maleimide (2kDa-5kDa) (Nanosoft Polymers #2667) (M-PEGPCL), or 
poly(lactide-co-glycolide)-PEG-maleimide (2kDa-5kDa) (M-PEGPLGA) (Nanosoft Polymers 
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#2794) was dissolved in N,N-dimethylformamide (BDH Chemicals #BDH83634.100) (DMF). In 
a 2 dram threaded vial, the solvent solution was injected via 0.5 mL syringe (BD #305602) by nano-
syringe pump (KD Scientific) into 1.4 mL continuously stirring Alexa Fluor 488 carboxylic acid 
tris(triethylammonium) salt (Invitrogen #A33077) (AF488) (0.114 mg/mL) in water at a constant 
rate of 5 μL/min. Unencapsulated AF488 was separated from loaded polymersomes by centrifugal 
filter device (Amicon 0.5 mL 100K #UFC5100BK), spinning three times at 14000g for 10 minutes 
in a 5424R centrifuge (Eppendorf).  
Encapsulation Efficiency and Polymersome Characterization – AF488 Encapsulation 
efficiency (EE) was determined with the following equation: 
𝐸𝐸𝐸𝐸(%) = 100% − (𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝑚𝑚𝑇𝑇𝑚𝑚𝑚𝑚 (𝑚𝑚𝑚𝑚) 𝑇𝑇𝑜𝑜 𝐴𝐴𝐴𝐴488 𝑖𝑖𝑖𝑖 𝑜𝑜𝑖𝑖𝑇𝑇𝑇𝑇𝑓𝑓𝑇𝑇𝑇𝑇𝑓𝑓𝑚𝑚0.16 𝑚𝑚𝑚𝑚  × 100%) 
Mass of AF488 in filtrates was calculated using a linear calibration curve (relative fluorescence 
units (RFU) vs. AF488 concentration). Fluorescence measurements were made with Synergy H1 
microplate reader (BioTek). Polymersome diameters, polydispersity index (PDI) and zeta potential 
were measured via Zetasizer Nano ZS (Malvern).  
Conjugation of CysTAT ligand to Polymersomes – 0.25 mg CysTAT(47-57) (Genscript 
#RP20343) (amino acid sequence: GRKKRRQRRRPQ) (CTAT) was added to aqueous solution of 
0.5 mg loaded, maleimide-functionalized polymersomes in water. Mixture was stirred overnight 
(~18 hours). Non-conjugated CTAT was separated from polymersomes by centrifugal filter device 
(Amicon 0.5 mL 100K #UFC5100BK), spinning three times at 14000g for 10 minutes in a 5424R 
centrifuge (Eppendorf). 
HEK293 Cell Culture and Treatment – HEK293 cells (ATCC #CRL-1573, verified by short 
tandem repeat profiling) were seeded in a 12-well plate, at 0.1 x 106 cells per well and incubated 
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for 24 hours at 37 °C and 5% CO2 in Delbecco’s modified eagle medium (Gibco #10313-021) 
(+10% FBS). At ~50% confluence, the cells were treated with 0.5 mg loaded M-PEGPLGA 
polymersomes in Delbecco’s phosphate buffered solution (Alfa Aesar #J61917) (PBS), 0.5 mg non-
loaded M-PEGPLGA polymersomes in PBS and 1 μL (2 mg/mL) AF488 in milli-Q water. Cells 
were allowed to incubate for 3.5 hours at 37 °C and 5% CO2. 
Flow Cytometry to Determine Polymersome Uptake – HEK293 cells removed from 12-well 
plate surface by cell scraper and 1 mL of cell suspension per sample was collected. Flow cytometry 
was performed to determine the mean cell FITC-A signal for each sample using a CytoFLEX LX 
(Beckman Coulter). 
Results and Discussion 
This chapter’s series of experiments is designed to show that by conjugating ligands to our 
polymersome drug carriers, we can introduce biological function, such as cell surface targeting and 
enhanced cellular uptake, beneficial to drug delivery. It this case, transactivator of transcription 
(TAT) of HIV will be the ligand and will act as a positively charged, cell-penetrating peptide (CPP) 
to increase cellular uptake of polymersomes. 
Embedding MPEGM in polymersome membrane – In an effort to locate maleimide functional 
groups to the surface of PEGPCL polymersomes, Varying masses of homobifunctional PEG 
polymers (MPEGM) were dissolved with 1.5 mg PEGPCL in the organic solvent. Polymersomes 
are then synthesized using solvent injection and stirred overnight with 0.25 mg cysteine-terminal 
TAT (CTAT). A thiol-maleimide conjugation reaction covalently bonds the CTAT to the PEG 
polymer embedded in the polymersome membrane. Table 3.1 shows the polymersome 
characteristics, measured by DLS both before and after conjugation with CysTAT peptide.  
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Table 3.1 – MPEGM - PEGPCL Polymersomes Before and After conjugation with CysTAT 
Peptide 
mg MPEGM 
per 1.5 mg 
PEGPCL 
CTAT Diameter (nm) PDI Zeta potential (mV) 
5mg - 92.71 0.118 -31.4 + 88.87 0.081 -20.9 
10mg - 92.33 0.103 - + 86.89 0.090 -20.3 
40mg - 88.94 0.117 -17.8 + 105.9 0.136 -10.0 
 
It would be expected, that if there was an appreciable amount of positively charged CysTAT peptide 
on the surface of the polymersomes, the zeta potential, a proxy for surface charge, would be 
positive, or at least have a large positive shift. However, after CysTAT conjugation, the 
polymersomes still show a significant negative zeta potential. This underwhelming result could be 
a consequence of either the lack of embedded homobifunctional PEG polymers. There may not be 
sufficient driving force for much the hydrophilic MPEGM to become embedded in the 
polymersome membrane. Instead the MPEGM would be free in solution and subsequently washed 
away by the centrifugal device. Without enough embedded MPEGM, there are not enough 
maleimides on the surface of the particles for the thiols of the CTAT to bind to. 
To eliminate complications derived from incomplete or heterogeneous embedding of MPEGM in 
the polymersome membrane, polymersomes were synthesized from PEG-based block copolymers 
in which a maleimide functional group was already covalently bonded to the terminal end of the 
PEG. For this purpose, maleimide functionalized PEG-polycaprolactone (M-PEGPCL) and PEG-
poly(lactide-co-glycolide) (M-PEGPLGA) were purchased (figure 3.2).  
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Figure 3.2 – Structure of Maleimide-Functionalized PEG-based Block Copolymers, (top) M-
PEGPCL. (bottom) M-PEGPLGA. 
Using solvent injection method, M-PEGPCL polymersomes are synthesized and characterized 
using DLS. These polymersomes have surprisingly small diameters and are quite polydisperse 
(figure 3.3 (top)). When a 50:50 blend of M-PEGPCL and PEGPCL is synthesized into 
polymersomes by solvent injection method, the resulting nanoparticles are more monodisperse, 
though still smaller than their non-functionalized counterparts from the previous chapter (figure 3.3 
(bottom)). 
 
Figure 3.3 – Size distribution (diameter) M-PEGPCL polymersomes (top) 100% M-PEGPCL 
(bottom) 50% M-PEGPCL, 50% PEGPCL. 
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When polymersomes were synthesized from M-PEGPLGA using solvent injection method, they 
were in the target diameter, PDI and zeta potential ranges established in the previous chapter (See 
Table 3.2 below). While PEGPCL is preferable because of its increased stability in the GBM tumor 
microenvironment, the following in vitro experiments are performed at neutral pH. As the purpose 
of this chapter is to demonstrate an increase in biological function by ligand attachment, the focus 
will be on conjugating M-PEGPLGA polymersomes with CTAT in an effort to increase cellular 
uptake. 
M-PEGPLGA polymersomes were synthesized by solvent injection method then stirred overnight 
with 0.25mg of CTAT peptide overnight. Table 3.2 shows diameter, PDI and zeta potential of these 
polymersomes both before and after CTAT conjugation.  
Table 3.2 – M-PEGPLGA Polymersomes Before and After Conjugation with CTAT Peptide 
M-PEGPLGA 
polymersomes CTAT 
conjugation  
Diameter (nm) PDI Zeta potential (mV) 
CysTAT - 90.29 0.133 -33.6 
CysTAT + 84.47 0.145 -0.723 
 
A large positive shift, 32.88 mV, is observed after CTAT conjugation, indicating a large number 
of covalently bonded CTAT peptide molecules on the surface of the polymersomes. 
Observing enhanced cellular uptake by fluorescence flow cytometry – M-PEGPLGA particles are 
synthesized by solvent injection with that the aqueous phase of the procedure containing 0.16 mg 
AF488 dye. The resulting polymersomes, measured by DLS, had diameters of 87.87 ± 5.96 nm, 
PDI of 0.145 ± 0.013, and zeta potentials of -39.2 ± 2.7 mV (n=3). Each batch of polymersomes 
was split and half of each sample was stirred with 0.125 mg CysTAT overnight. HEK293 cells 
were treated with the loaded polymersomes, both CysTAT- conjugated and unconjugated, for 3.5 
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hours. The cells were analyzed on a flow cytometer to determine the mean fluorescence (FITC) of 
each cell population. Normalizing for cell autofluorescence, the mean fluorescence of cells treated 
with CysTAT-conjugated increased nearly two-fold over those treated with nonconjugated 
polymersomes (Figure 3.4). 
 
Figure 3.4 – Fold change in mean fluorescence (FITC) per HEK293 cell treated with AF488- 
loaded CTAT-Functionalized and non-functionalized M-PEGPLGA polymersomes 
 
Conclusions and Future Outlook 
This chapter illustrates that polymersomes are not just a platform for delivering drug combinations 
and extending drug circulation times in patients, but rather they can be functionalized to perform 
specific biological functions. In this case, CysTAT ligands increased the rate of cellular uptake of 
polymersomes, albeit indiscriminate of cell type. The system is modular, and using similar 
bioconjugation techniques, a variety of macromolecules, antibodies, peptides, proteins etc. can be 
conjugated to a polymersome surface. In the context of local delivery, particularly in GBM, using 
ligands that will increase cellular uptake or adhesion to tumor-specific cell types is an attractive 
option. 
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Moving forward, the importance of discovering biologically relevant ligands that are specific to the 
treatment of specific diseases is paramount, as is optimizing bioconjugation techniques to attach 
the ligands to therapeutic polymersomes. This flavor of biology-specific functionalization of 
polymersomes could be used to increase drug delivery efficacy for a variety of genetic disorders 
and cancers. For GBM, a methodology for finding tumor-specific targets, and the ligands that will 
help target them, will be touched on in the next chapter. 
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4 – TARGETTING GBM USING mRNA DATA 
Introduction 
In previous chapters, it was demonstrated that PEG-polyester polymersomes were potentially 
suitable candidates for delivering encapsulated drugs locally to GBM. Furthermore, those 
polymersomes can be functionalized with ligands designed to target and improve drug delivery 
efficiency to cells. The goal of this chapter is to elucidate GBM surface proteins that, when targeted, 
will facilitate an increase in therapeutic efficacy of drug-loaded polymersomes. 
The phenotypic heterogeneity of GBM tumor cells confounds the discovery of an effective cellular 
surface target. Within a single GBM tumor, there are distinct populations of tumor cells with 
varying levels of protein expression27–29,31,81. These populations of tumor cells change phenotypes 
in response to stimuli, including immune responses to surgery and chemotherapy82–84. However, 
systems biologists have been able to employ genetic, transcriptomic and proteomic data to classify 
and quantify heterogeneity of GBM tumor cells in a number of useful ways. Researchers are 
combining new surgical sampling techniques with genomic analysis to track the evolution 
dynamics of tumor cell populations31. Other biologists are using single-cell transcriptomic data and 
gene-expression based analysis in an effort classify distinct GBM subtypes for future 
researchers27,59. Furthermore, databases like the Cancer Genome Atlas (TCGA), Cancer Cell Line 
Encyclopedia (CCLE) and International Cancer Genome Consortium (ICGC) provide enormous, 
curated, cancer-specific datasets that help inform the fields of drug discovery and pharmacology60. 
This chapter will focus on using a combination of databases to identify a set of highly expressed 
GBM tumor cell surface targets and the ligands that bind to them. These ligands can be conjugated 
to drug-carrying polymersomes, creating a combination therapy platform designed to target 
multiple GBM cell phenotypes in the same tumor. 
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Methods 
Determining High Expression Transcripts in GBM – Feltus TCGA GEM analysis - A gene 
expression matrix (GEM), describing fragments per kilobase million (FPKM) of 73599 mRNA 
transcripts across 2016 cancerous tumor samples [bladder, thyroid, ovarian, low-grade glioma, 
glioblastoma, data from The Cancer Genome Atlas (TCGA)] was built by William Poehlman 
(Department of Genetics and Biochemistry, Clemson University), which had been previously 
quantile normalized and values converted to log2 values (No outliers detected using Kolmogorov-
Smirnov test)85. From Dr. Alex Feltus (Department of Genetics and Biochemistry, Clemson 
University), a key was obtained to convert the knowngene5 UC-Santa Cruz genome database gene 
model identifiers to Ensembl gene identifiers, and the transcripts that had no Ensembl ID were 
omitted from the GEM. A median FPKM value across the 174 GBM tumor samples was obtained 
for each transcript. The transcripts with the 12000 highest median FPKM values were used to 
determine genes of high expression in GBM. Westfall TCGA GEM Analysis – RNASeq expression 
profiles for 174 GBM tumor samples were downloaded from the TCGA (10/30/2018). The profiles 
were merged to form a single GEM. Using python, the data was quantile normalized, and FPKM 
values were converted to log2. A median FPKM value across the tumor samples was obtained for 
each transcript. The transcripts with the 12000 highest median FPKM values were used to 
determine genes of high expression in GBM. (Python code: TCGA_analysis_FELTUS, 
TCGA_Analysis_Westfall in Appendix A) 
Comparing High Expression GBM Transcripts Against Normal/Low Expression in Normal 
Brain Tissue – A GEM, describing FPKM of 56202 mRNA transcripts across 1671 non-diseased 
brain tissue samples from the Genotype-Tissue Expression project (GTEx)86, was obtained from 
Dr. Alex Feltus (Department of Genetics and Biochemistry, Clemson University), which had been 
previously quantile normalized and converted to log2 values. A median FPKM value across the 
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tissue samples was obtained for each transcript. The transcripts with the 5000 highest median 
FPKM values were used to determine genes of high expression in healthy brain tissue and were 
omitted from the data. The remaining transcripts in the GEM were considered to be of normal or 
low expression. The Ensembl gene IDs of the high expression transcripts in the Feltus/Westfall 
TCGA GEMs were compared with the Ensembl gene IDs of the normal/low transcripts. Any 
overlap in the set identifies a transcript that is highly expressed in GBM and not highly expressed 
in non-diseased brain tissue. (Python Code: GTEX_analysis, 
TCGA_GTEX_Comparison_FELTUS, TCGA_GTEX_Comparison_Westfall, 
Westfall_Feltus_TCGA_COMPARE in Appendix A) 
Gene Ontology Annotations to Find Candidate Surface Proteins and Corresponding Binding 
Ligands – Ensemble gene IDs of transcripts categorized as highly expressed in GBM and 
normal/low expressed in non-diseased brain tissue are uploaded to Uniprot87 where the gene 
ontology (GO) annotations are listed for each gene. QuickGO88 is used to search for GO annotations 
that identify surface proteins which can be potentially targeted with ligands. Gene IDs for the high 
GBM/low non-diseased transcripts are filtered with the surface protein GO annotations to reveal 
“candidate genes” as coding for proteins that are potential ligand binding sites for GBM drug 
delivery. Candidate genes are cross-checked individually against the Gene Expression Profiling 
Interactive Analysis (GEPIA) portal89 to verify that gene has high expression in GBM tumor 
samples and normal/low expression in non-diseased brain tissue. To find corresponding binding 
ligands, the candidate genes were searched for in the literature-informed online databases Binding 
DB90 and RCSB Protein Data Bank91. 
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Experimental Results and Discussion 
To find GBM surface proteins for active targeting and the ligands that can be used to target them, 
it is necessary to leverage mRNA transcriptome data from the TCGA and GTEx. The workflow to 
go from RNAseq data to GBM-specific ligand molecules incorporates a combination of Python 
programming and online databases, including GEPIA, Uniprot, QuickGO, RCSB Protein Data 
Bank, and Binding DB. The workflow shown in Figure 4.1 illustrates how Python isolates and 
compares 73599 mRNA transcripts from TCGA and GTEx to identify genes that are highly 
expressed in GBM tumor samples, but not in healthy, non-diseased brain tissues. Using this 
method, depending on the source of the TCGA GEM (Feltus or Westfall), there are between 5400 
and 7100 transcripts from candidate genes. 
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Figure 4.1 – Illustrative view of workflow identifying candidate genes 
Genes identified in this way are uploaded to Uniprot, where groups of genes can be grouped 
according to their Gene Ontology (GO) annotations. These annotations identify the many molecular 
function, biological process, and cellular component attributes of the proteins these genes encode 
for. GO annotations that can identify relevant cellular surface targets can be found using QuickGO. 
Candidate genes found to code for the biologically relevant target proteins are then cross-checked 
against the GEPIA online database, where expression of individual genes in tumor and healthy 
tissue can be visualized based on RNAeq data. This is done as a second check to validate that the 
initial python scripts correctly identified transcripts that were indeed abnormally expressed in GBM 
tumor samples. These proteins for which candidate genes encode are then run on databases that 
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have ligand binding information based on previous literature, most likely Binding DB or the RCSB 
PDB. Figure 4.2 illustrates how gene expression is visualized in by boxplot in GEPIA (axis 
representing transcripts per kilobase million (TPM+1)) and the identification of ligands with 
binding affinity for the expressed protein.  
 
Figure 4.2 – Illustrative view of candidate gene/protein GEPIA verification and ligand selection. 
(top) PLAUR (bottom) CXCR4. Boxplots are generated by GEPIA89. Axis is mRNA transcripts 
per kilobase million (log-2). GBM tumor samples are depicted in red, with healthy brain tissue 
samples in gray.  
Figure 4.2 also shows two candidate genes/proteins, Urokinase plasminogen activator surface 
receptor (PLAUR) and C-X-C chemokine receptor type 4 (CXCR4). PLAUR is located in the 
GEPIA RCSB 
PDB 
GEPIA 
Binding 
DB 
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plasma membrane and is shown to have high binding affinity to 2-Amino-5-phenyl-1-pyridin-2-
ylpyrrole-3-carbonitrile according to literature found using BindingDB92. CXCR4 is a 
transmembrane protein that has a high binding affinity for (6,6-dimethyl-5,6-dihydroimidazo[2,1-
b][1,3]thiazol-3-yl)methyl N,N'-dicyclohexylimidothiocarbamate, per the literature found in RCSB 
PDB93. According to data from GEPIA, transcripts for PLAUR and CXCR4 are found in 
significantly higher amount in GBM tumor samples, when compared to healthy non-diseased brain 
tissue93. These characteristics (location, binding affinity and mRNA expression) make PLAUR and 
CXCR4 good candidates as part of a set of GBM surface targets for targeting with functionalized 
polymersomes.  
Conclusions and Future Outlook 
In this chapter, it has been shown that analysis of large RNAseq datasets can be combined with 
extensive data from online transcriptomic and proteomic databases, revealing disease-specific 
biologic targets for local drug delivery. This mRNA-to-ligand workflow is great for identifying 
GBM targets but can easily be adopted to accommodate other cancers or diseases. It is not 
unreasonable to image a workflow like this being adapted for patient- or tumor-derived RNAseq 
data and used to develop personalized cancer-targeting drug carriers. 
While promising, it is important understand the limitations of this analysis. While there is evidence 
that intracellular mRNA levels are correlative with cellular protein levels94–97, there are also 
researchers that caution that the correlation is poor and not properly understood98–100. They suggest 
that mRNA to protein correlation may be affected by tissue specific factors and epigenetics. 
However, as the methods for collecting transcriptomic and proteomic continue to improve, and 
abundance of data available increases, it is likely that understanding of the mRNA and protein level 
correlation will improve, giving strength to the type of analysis performed in this chapter. 
36 
 
Nevertheless, protein level measurements are crucial as additional confirmatory validation step in 
future work. 
Moving forward, this analysis must be expanded in two ways. First, it is important to find more 
candidate genes for GBM. Finding these genes will likely be the result of identifying more GO 
annotation combinations indicating a particular protein is a good biological candidate for targeting, 
thus expanding the search scope through the highly expressed GBM genes. It is also important to 
verify sets of candidate genes are not overexpressed exclusively in the same tumor samples. With 
the current dataset of 174 samples, there is likely some overlap of overexpressed genes, but the 
goal should be to identify a set of genes that minimizes correlative overexpression of the candidates. 
Second, in vitro cellular uptake experiments can be performed on candidates as they are identified. 
Cell lines can be transformed to overexpress the candidate protein on the cell surface. Drug or 
fluorophore-loaded polymersomes will then be conjugated with the binding ligand associated with 
that protein, as in Chapter 3. The expectation is that higher drug/fluorophore payloads will be 
internalized by the transformed cells when the loaded polymersomes have been conjugated with 
the targeting ligand, quantified by cell death or flow cytometry fluorescence. 
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5 – THE CHEMOTAXIS HYDROGEL 
Introduction 
In an earlier chapter, the concepts of drug-loaded and nanoparticle-loaded hydrogels were 
introduced. Extensive research optimizing these systems, employing innovative materials and 
informed by modern understanding of disease biology, has been performed over the last 
decade37,38,40,54,56,101. However, the ultimate goal for these systems has remained the same: to 
efficiently deliver therapeutics to a location/cell/tumor in the effort to treat or eliminate the disease. 
However, modern technologies are allowing researchers to ponder quite the opposite: bringing the 
diseased cells to the therapeutic location for elimination. 
There are a few researchers currently creating and optimizing hydrogels that are great candidates 
for cell migration: PEG based hydrogels, crosslinked by enzyme degradable peptides (EDP). These 
PEG-EDP hydrogels mimic the extracellular matrix of the human body and are capable of 
encapsulating cells and providing an environment for the cells to migrate. When the cell’s receptor 
contacts the EDPs, mobility pathways in the cell are activated and the cell excretes the appropriate 
degrading enzyme and migrates through the gel102–106. 
This chapter focuses on taking the concepts of the PEG-EDP hydrogel and framing them as a tool 
for local treatment of cancer. The hydrogels can act as a “black hole”, allowing invasive tumor 
cells, particularly those left after tumor resection, to invade instead of migrating to the surrounding 
tissue. The direction of the cell migration, that is toward the hydrogel, can be manipulated using a 
chemoattractant gradient107,108 (Figure 5.1).  
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Figure 5.1 – Illustration demonstrating that eukaryotic cells migrate along a gradient toward a 
higher concentration of chemoattractants. Adapted from107. 
 
Chemotaxis is the process by which that mammalian cells migrate toward the higher concentration 
of chemical signals, which will in this case, be originating from the hydrogel. 
Methods 
Synthesis of Chemotaxis Hydrogel – 50 mg maleimide-functionalized 4-arm polyethylene glycol 
(20KDa) (JENKEM Technology USA # A7029-1) (4armPEG) was dissolved in 0.5 mL milli-Q 
water, varying concentrations of enzyme degradable peptide (Genscript #UI630DK260-1) (amino 
acid sequence: CIPESLRAGC) (EDP) (20,40,100 mg/mL) was dissolved in 0.5 mL of milli-Q 
water and added to 4armPEG solution and vortexed for 1 second. Mixture was quickly pipetted 
into 12-well plate and allowed ~2 hours to gelate.  
Determination of Hydrogel Stiffness – Stiffness of hydrogel was determined using Poroelastic 
relaxation indentation (PRI). A custom-built apparatus for performing PRI was provided by Dr. 
Eric Davis and operated by Nick Gregorich (Department of Chemical and Biomolecular 
Engineering, Clemson University). A high-resolution linear actuator (M-230, physike intrumente) 
was connected to a S-beam load cell (Futek LSB200, FUTEK Advanced Sensor Technology, Inc) 
with a rigid glass indenter of radius of curvature R = 5.187mm. The actuator was mounted to a 
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high-performance linear stage with 46mm of travel range (M433, Newport). The indenter was 
lowered by the actuator at a speed of 3 μm/s until contact with the hydrogel was reached. Upon 
contact the indenter velocity changed to 10 μm/s until a load of 29.4mN was reached. The indenter 
was held, fixed for 5 seconds, and released from the sample. A LabVIEW custom program, written 
by Jaime Idarraga-Mora (Department of Chemical and Biomolecular Engineering, Clemson 
University), was used to acquire load and indenter height data as a function of time from the S-
beam load cell during the experiments. Hooke’s law was used to calculate Young’s modulus from 
collected data109. 
Transwell Invasion Assay – Cell Culture – MDA-MB-231 cells and U-87 MG cells (ATCC 
#HTB-26, ATCC #HTB-14, both verified by short tandem repeat profiling) were seeded in separate 
T-75 flasks, at 2.0 x 106 cells per flask, and incubated for 36-48 hours at 37 °C and 5% CO2, in full 
media Delbecco’s modified eagle medium (Gibco #10313-021) (DMEM +10% FBS +2mM L-
glutamine). Hydrogel inserts – 1 mL Chemotaxis hydrogel was synthesized and split into two 
separate aliquots. 1 μg Doxorubicin-HCL (Fisher #BP2516-10) (DOX) was added to one of the 
aliquots. For each cell line, 75 μL hydrogel was added to a 6.5 mm Transwell permeable support 
with 80 μm pore (Costar #3422), and 75 μL hydrogel+DOX was added to another insert. Insert 
hydrogels were allowed 2 hours to gelate. Each insert hydrogel was soaked overnight in starving 
media (DMEM with no additives), or until hydrogel was visibly saturated. Cell migration – At 
~70% confluence, MDAMB231 and U87 cells were lifted from T-75 flask with 0.25% Trypsin-
EDTA (Gibco #25200056), centrifuged, aspirated, then resuspended in starving media (DMEM 
with no additives) to a concentration of 1.0 x 106 cells/mL. For each cell line, 100 μL (1.0 x 105 
cells) were placed on top of a hydrogel inset, a hydrogel+DOX insert and a blank insert (directly 
on membrane). Inserts were placed in 24-well plate containing 550 μL assay media (DMEM +0.5% 
FBS +2mM L-glutamine +2ng/mL EGF). Plates, containing cells and inserts are incubated for 48 
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hours at 37 °C and 5% CO2. Plate wells were inspected under Revolve microscope (Echo 
Laboratories) at 10x magnification to determine, qualitatively, whether cells had migrated through 
the membrane and adhered to well surface. 
Experimental Results and Discussion 
The goal of the set of experiments in this chapter is to formulate a hydrogel from PEG and an 
enzyme degradable peptide (EDP) that is degradable by one or more matrix metalloprotease. Also, 
the hydrogel should have a stiffness similar to the tissue type it will be implanted into, which for 
the purposes of treating GBM, is brain tissue. Furthermore, the hydrogel should facilitate cell 
migration through degradation of the EDP, similar to the way a cell moves through the ECM. 
Hydrogel formulation and gelation – This experiment was designed and performed by Chad Eaton 
(Department of Bioengineering, Clemson University). A peptide sequence, CIPESLRAGC, 
degradable by MMP-2105 (linker), was purchased and used to crosslink 4-Arm PEG functionalized 
with terminal maleimides (4ARMPEG). Figure 5.2 illustrates the covalent bonding reaction 
between the maleimide groups and the sulfhydryl pendant groups of the terminal cysteines of the 
EDP.  
 
Figure 5.2 – Crosslinking of hydrogel by covalent bonding of maleimide functionalized 4-Arm 
PEG to sulfhydryl pendant group 
50 mg 4ARMPEG in 0.5 mL Milli-Q water is combined quickly with 20 mg linker in 0.5 mL Milli-
Q Water. The transparent hydrogel forms and gelates completely in ~2 hours. 
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Determining hydrogel stiffness – This experiment was designed and performed by Chad Eaton and 
Riley Rapert (Department of Bioengineering, Clemson University) with assistance and equipment 
provided by Nick Gregorich and Dr. Eric Davis (Department of Chemical and Biomolecular 
Engineering, Clemson University). Now that a hydrogel can be formulated, it is important to 
determine whether the hydrogel is a stiffness that is close to biological tissue, and whether that 
stiffness can be modulated by formulation. 
A set of hydrogels was synthesized by keeping the amount of 4ARMPEG constant and varying the 
amount of linker. 50 mg 4ARMPEG in 50 mL Milli-Q water was combined with varying masses 
of linker in 50 mL Milli-Q water and allowed to gelate for 2 hours (Table 5.1). Poroelastic 
Relaxation Indentation (PRI) analysis was performed to determine Young’s modulus, a measure of 
mechanical stiffness109,110. The following equation, a derivation of Hooke’s Law, was used: 
𝐸𝐸 = (1 − 𝑣𝑣2)
𝜋𝜋
∆(𝑃𝑃ℎ)
∆𝑓𝑓
 
Where P is the load, h is the probe depth and r is the radius of contact of the spherical probe. An 
assumption is made that the substance is isotropic, meaning that the stiffness will be the same in 
the hydrogel regardless of direction. Thus, ν is assumed to be 0.5. Table 5.1 shows the Young’s 
modulus of each formulation. 
Table 5.1 – Chemotaxis Hydrogel Formulation and Young’s Modulus 
Hydrogel 4ARMPEG (mg/mL 
H2O) 
Linker (mg/mL H2O) Young’s modulus 
(kPa) 
1 100 20 1.21 
2 100 40 1.86 
3 100 100 2.01 
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There is a positive correlation between the amount of linker used and the stiffness of the hydrogel. 
Figure 5.3 shows the typical Young’s modulus for a variety of tissue types, according to their 
Collagen-1 content111. GBM tumor varies from 0.5 - 2 kPa. This indicates that the hydrogels 
formulated are similar in stiffness to GBM tumor. Also, it is shown that stiffness of the hydrogel 
can be modulated by varying the amount of cross-linker available during gelation. 
 
Figure 5.3 – Tissue stiffness for normal tissues. Highlighted in blue is a range of stiffnesses for 
GBM tumors. Adapted from111 
 
Cell invasion assay – This experiment was designed and performed by Asia Paguntalan 
(Department of Genetics and Biochemistry, Clemson University). The goal of this experiment is to 
observe, and quantify, movement of cells into or through the hydrogel toward a chemotaxis signal.  
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A common way to quantify movement of cells toward chemoattractants is a transwell membrane 
invasion assay. The assay was modified such that thin chemotaxis hydrogels would be formed 
across the inserts above the membrane (Figure 5.4). 75 μL hydrogel (same formulation as hydrogel 
#2 in table 5.1) was added and gelated on top of the membrane in the insert, then soaked in DMEM 
with no additives. The receiver well was filled with DMEM +0.5% FBS +2mM L-glutamine 
+2ng/mL Epidermal growth factor (EGF). The EGF is a chemoattractant for the invading 
MDAMB231 breast cancer cells and the U87 glioblastoma cells. It is expected that the EGF would 
diffuse through the hydrogel, creating a gradient, that would signal the cells to migrate toward the 
receiver well through the hydrogel by degrading the EDP linker. Cells, in DMEM (with no 
additives) were deposited on top of the hydrogel and incubated for 48 hours at 37 °C and 5% CO2.   
 
Figure 5.4 – Illustration of transwell invasion assay modified for chemotaxis hydrogel 
 
Unfortunately, in every trial, both U87 and MDAMB231 cells, microscope inspection, failed to 
migrate through the hydrogel and membrane and into the receiver well. Upon further inspection, 
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the cells seemed to have remained above the hydrogel entirely. It may be unrealistic to assume 
that in 48 hours, EGF would diffuse across the hydrogel and the cells would invade and 
transverse through the hydrogel, which is approximately 2mm thick after soaking in media. The 
assay can be modified such that the thickness of the gelated hydrogel in the insert is closer to that 
of a thin film. Another modification to this experiment is to embed the cells in the hydrogel as it 
gelates. Specifically, instead of dissolving 50mg of 4ARMPEG in 0.5 mL of Milli-Q water, 
dissolve it in 0.5 mL of cell suspension in media. This approach would lower the time for 
diffusing EGF to reach the cells, as they would already be dispersed in the hydrogel.  
Conclusions and Future Outlook 
This chapter is an illustrative example of innovative materials design, generated by eschewing the 
traditional “drug-loaded-hydrogel” delivery concept. These experiments are preliminary work 
towards a goal of making a modular platform of disease-fighting chemotaxis hydrogels. The EDP 
crosslinker chosen for this work can be interchanged with dozens of other EDPs, each specific to 
mobility enzymes secreted by cells of varying tumor type. RNAseq analysis, described in the 
previous chapter, can even reveal which chemotaxis signal receptors are expressed in a specific 
tumor type, in turn, informing which chemoattractants would be most effective for the system. 
Furthermore, this analysis shows that the chemotaxis hydrogel stiffness can be modulated through 
formulation, allowing these hydrogels to be implanted in a variety of tissue types. 
Moving forward, the most important focus will be observing and quantifying cell movement 
through the hydrogel. Likely, the best way to accomplish this is thorough automated, 3D live-cell 
imaging, where cells can be tracked in real-time. Hydrogels can be synthesized, using a cell 
suspension in lieu of Milli-Q water, embedding the cells in the hydrogel, in multi-well plates. An 
automated imaging system like the Cytation 5 and Biospa (BioTek) can be used to image the cells 
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in the hydrogels over several days, with the imaging software tracking selected cells. Furthermore, 
chemotaxis signals can be injected at the edge of the well and allowed to diffuse, creating a gradient 
across the hydrogel. This will show, qualitatively, whether migration direction of cells in the 
hydrogel can be controlled by chemotaxis signaling. 
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APPENDIX A – PYTHON CODES 
All Jupyter notebooks, containing these codes, are located on Birtwistle Lab Microsoft OneDrive 
(Folder: GBM Westfall) 
 
Dependent Files: 
 
All files are located on Birtwistle Lab Microsoft OneDrive (Folder: GBM Westfal) 
TCGAV1.txt 
TCGAIDtoESNID.txt 
GTEXV1.txt 
DATA (contains .txt files TCGA used for TCGA_analysis_Westfall) 
 
TCGA_analysis_FELTUS 
import pandas as pd 
 
df = pd.read_table("TCGAV1.txt", index_col=0) 
 
df.index.name = 'TCGA_ID' 
 
GBM={} 
 
for i in range(2016):  
    if df.iloc[:,i].name.startswith('GBM'): 
        GBM[df.iloc[:,i].name]=df.iloc[:,i] 
 
GBMData=pd.DataFrame(data=GBM) 
 
GBMData['Median'] = GBMData.median(axis=1) 
 
ensids = pd.read_table("TCGAIDtoENSID.txt", sep=' ', index_col=0) 
 
GBMData = GBMData.join(ensids, how='outer') 
 
GBMData.sort_values(by='Median', ascending=False, inplace=True) 
 
with_ensid = GBMData[GBMData['Ensembl_Gene_ID'].notnull()] 
 
largest_median_with_ensid = with_ensid[['Median','Ensembl_Gene_ID']][:12000] 
 
largest_median_with_ensid['Ensembl_Gene_ID'].to_csv(r'C:\Users\jjwes\Documents\Python 
Workspace\GBM\topTCGA.txt',index=0) 
 
largest_median_with_ensid.to_csv(r'C:\Users\jjwes\Documents\Python 
Workspace\GBM\TCGA_high.txt') 
 
TCGA_analysis_Westfall 
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import pandas as pd 
 
import numpy as np 
 
import glob 
 
files = glob.glob('**/*.FPKM.txt', recursive=True) 
 
base = {} 
 
base_frame = pd.DataFrame(base) 
for i in range(len(files)): 
    base_frame[files[i]] = pd.read_table(files[i],index_col=0, names=['FPKM'])['FPKM'] 
 
FPKM=base_frame 
 
rank_mean = FPKM.stack().groupby(FPKM.rank(method='first').stack().astype(int)).mean() 
 
FPKM_Qnormal=FPKM.rank(method='min').stack().astype(int).map(rank_mean).unstack() 
 
FPKM_Qnormal_Nan = FPKM_Qnormal.replace(0, np.nan) 
 
Log2_Qnormal_Nan = np.log2(FPKM_Qnormal_Nan) 
 
Log2_Qnormal=Log2_Qnormal_Nan.replace(np.nan,0) 
 
Log2_Qnormal.index.name = 'Ensembl_Gene_ID' 
 
Log2_Qnormal['Median'] = Log2_Qnormal.median(axis=1) 
 
Log2_Qnormal.sort_values(by='Median', ascending=False, inplace=True) 
 
Log2_Qnormal.index=Log2_Qnormal.index.str[:15] 
 
largest_median_TCGA_WESTFALL = Log2_Qnormal[['Median']][:12000] 
 
largest_median_TCGA_WESTFALL.to_csv(r'C:\Users\jjwes\Documents\Python 
Workspace\GBM\TCGA_high_WESTFALL.txt') 
 
GTEX_analysis 
import pandas as pd 
 
GTEXData = pd.read_table("GTEXV1.txt") 
 
GTEXData['Median'] = GTEXData.median(axis=1) 
 
GTEXData.sort_values(by='Median', ascending=True, inplace=True) 
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GTEXData.index=GTEXData.index.str[:15] 
 
GTEX_smallest_median = GTEXData['Median'][:50000] 
 
GTEX_smallest_median.to_csv(r'C:\Users\jjwes\Documents\Python 
Workspace\GBM\GTEX_low.txt') 
 
TCGA_GTEX_Comparison_FELTUS 
import pandas as pd 
 
import numpy as np 
 
TCGA_high = pd.read_table('TCGA_high.txt', sep=',',index_col=0) 
 
GTEX_low = pd.read_table('GTEX_low.txt',sep=',',names=['Ensembl_Gene_ID','Median']) 
 
p=0 
 
for i in range(12000): 
    if 
GTEX_low['Ensembl_Gene_ID'].str.contains(TCGA_high['Ensembl_Gene_ID'].iloc[i]).any(): 
        print (TCGA_high['Ensembl_Gene_ID'].iloc[i]) 
        p=p+1 
 
p 
 
TCGA_GTEX_Comparison_Westfall 
import pandas as pd 
 
import numpy as np 
 
TCGA_high_WESTFALL = pd.read_table('TCGA_high_WESTFALL.txt', sep=',',index_col=0) 
 
GTEX_low = pd.read_table('GTEX_low.txt',sep=',',names=['Ensembl_Gene_ID','Median']) 
 
p=0 
 
for i in range(12000): 
    if GTEX_low['Ensembl_Gene_ID'].str.contains(TCGA_high_WESTFALL.index[i]).any(): 
        print (TCGA_high_WESTFALL.index[i]) 
        p=p+1 
 
p 
 
Westfall_Feltus_TCGA_COMPARE 
TCGA_high_F = pd.read_table('TCGA_high.txt', sep=',',index_col=0) 
 
TCGA_high_W = pd.read_table('TCGA_high_WESTFALL.txt', sep=',',index_col=0) 
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p=0 
 
for i in range(12000): 
    if TCGA_high_W.index.str.contains(TCGA_high_F['Ensembl_Gene_ID'].iloc[i]).any(): 
        print (TCGA_high_F['Ensembl_Gene_ID'].iloc[i]) 
        p=p+1 
 
p 
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